Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 47.9%

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the target of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 103,200 shares, an increase of 47.9% from the September 15th total of 69,800 shares. Currently, 3.0% of the shares of the company are short sold. Based on an average daily volume of 1,640,000 shares, the short-interest ratio is currently 0.1 days.

Alzamend Neuro Price Performance

ALZN traded up $0.06 during mid-day trading on Friday, reaching $1.66. 118,368 shares of the company traded hands, compared to its average volume of 545,148. The company’s fifty day moving average price is $2.19 and its 200-day moving average price is $4.57. Alzamend Neuro has a 52-week low of $1.40 and a 52-week high of $33.57.

Alzamend Neuro (NASDAQ:ALZN) last posted its quarterly earnings data on Wednesday, September 11th. The company reported ($1.25) EPS for the quarter, beating analysts’ consensus estimates of ($2.38) by $1.13. On average, equities analysts anticipate that Alzamend Neuro will post -14.27 EPS for the current year.

Institutional Trading of Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Virtu Financial LLC acquired a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned 0.38% of Alzamend Neuro at the end of the most recent reporting period. 49.61% of the stock is owned by institutional investors and hedge funds.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.